A team at Atlas Venture began working on how to deliver small interfering RNA (siRNA) to the kidney three years ago and created a platform similar to technologies that have emerged for delivering oligonucleotides to the liver. Now, Judo Bio, the company that Atlas incubated to develop siRNA therapeutics and other genetic medicines delivered to the kidney, has emerged from stealth mode with $100m in seed funding and series A venture capital to advance its first drug candidates.
Judo Bio Emerges With $100m To Deliver siRNA Therapeutics To The Kidney
Launches With Preclinical Technology Platform Data
Judo Bio, incubated for three years by Atlas Venture to deliver siRNA and other genetic medicines to the kidney, came out of stealth mode with $100m and new CEO Rajiv Patni.
